Results 151 to 160 of about 106,021 (225)

Crashing by design: Utilizing DNA damage for MCC differentiation. [PDF]

Trends Cell Biol
Suva EE, Mitchell BJ.
europepmc   +1 more source

From Germline Susceptibility to Therapeutic Vulnerability: DNA Damage Response Gene Mutations Driving Multiple Myeloma Evolution and Precision Therapy. [PDF]

Hum Mutat
Shen Q, Wang Y, Cai L, Qian J.
europepmc   +1 more source

Molecular insights into DNA damage response plasticity in glioma stem cells. [PDF]

Commun Biol
Molinari NC, Lusi V, Bianconi A, De Pasquale D, Giunti D, Fiaschi P, Cerutti E.   +6 more
europepmc   +1 more source

Long-Term PET-Nanoplastic Exposure Alters DNA Damage Response Capacity in BEAS-2B Human Bronchial Epithelial Cells. [PDF]

Int J Mol Sci
Morataya-Reyes M, Villacorta A, Egea R, Martín-Pérez J, Gutiérrez-García J, Pastor S, Marcos R, Hernández A.   +7 more
europepmc   +1 more source

CDK7 as a Potential Exploratory Biomarker for Distinguishing Acute Myocardial Infarction Subtypes via DDR Pathways: Evidence From a Bangladeshi Cohort. [PDF]

Clin Cardiol
Ripon RH, Zahin H, Noman AA, Saba AA, Sayem M, Nabi AHMN, Yasmin T.   +6 more
europepmc   +1 more source

Landscape of DNA damage response (DDR) genes alterations in the prospective MOSCATO and MATCH R trials

Annals of Oncology, 2017
Y. El Dakdouki, L. Verlingue, C. Massard, R. Bahleda, A. Hollebecque, L. Mahjoubi, E. Rouleau, L. Lacroix, N. Auger, J.-Y. Scoazec, E. Solary, A. Marabelle, F. André, J.-C. Soria, S. Postel-Vinay   +14 more
openaire   +1 more source

Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: A pan-cancer perspective on precision oncology. [PDF]

Neoplasia
Zhu H, Shao J, Wang Y, Gu C, Liu J.
europepmc   +1 more source

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer. [PDF]

Front Oncol
Karam MN, Hajj J, Crane CH, Ramia P, Geara F, Hamadeh N, Scott JG, Grobmyer S, Almond R, O'Reilly EM, Hajj C.   +10 more
europepmc   +1 more source

SLFN11 expression as a marker of small cell lung cancer vulnerability to combined PARP inhibitors and immune checkpoint inhibitors during maintenance. [PDF]

J Thorac Dis
Pujol JL.
europepmc   +1 more source